ArticleResearch and practice in thrombosis and haemostasis2025
Marstacimab, an antitissue factor pathway inhibitor, combined with bypassing agents: effects on thrombin generation and in hemostatically normal rats.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Marstacimab is an antitissue factor pathway inhibitor recently approved for treatment of hemophilia without inhibitors and under investigation for treatment of hemophilia with inhibitors. Management of hemophilia in people with inhibitors frequently requires the use of bypassing agents such as recombinant activated factor (F)VII (rFVIIa), activated prothrombin complex concentrate (aPCC), or plasma-derived FVIIa (pdFVIIa)/FX mixture (pdFVIIa/FX). Objectives: We explored the potential for excessive thrombin generation and potential additive effects of concomitant administration of marstacimab and bypassing agents. Methods: An Results: Conclusion: These findings suggest marstacimab in combination with pdFVIIa/FX can increase hemostasis without excessive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.